DCT is seeking an experienced CAR-T scientist to work alongside an excellent scientific team and report directly to the Head of Drug Discovery. The successful candidate will have a strong background in immunology, with experience in T cell biology and cellular therapies. The successful candidate will independently design and perform experiments, lead a project, and play central roles in pre-clinical and early clinical development of first product candidates working amongst a highly collaborative and entrepreneurial team of clinicians and scientists. The successful candidate should be dedicated to contributing to all aspects of the company’s development. This position is an excellent opportunity to gain valuable experience and has significant potential for promotion.
- BS/MS or PhD in immunology or a related field with a strong publication record
- 5+ of experience studying T or NK cell biology, cellular engineering, and/or autologous cell manufacturing and therapy is required
- Industry experience and expertise managing CROs is preferred
- Experienced in engineering primary human T cells using viral vectors, such as lentivirus
- Excellent technical skills handling primary immune cells and performing standard immunological assays (cytotoxic assays, multi-parametric flow cytometry, ELISpot, and other cellular immunology techniques)
- Strong analytical and data analysis skills (including use of FlowJo and Prism)
- Team player with excellent written, verbal, and presentation skills
- Ability to thrive on tight deadlines and adapt to new challenges
- Ambitious and driven to build a startup from the ground up
Competitive salary commensurate with market and experience. We are willing to consider more qualified candidates and can adjust responsibilities and salary, accordingly.
Dynamic Cell Therapies (DCT) is an exciting venture funded emerging cell therapy company developing controllable chimeric antigen receptor (CAR) T cells for cancer immunotherapy, based on a transformative technology developed in the laboratory of Dr. Carl Novina at the Dana-Farber Cancer Institute. Launched in the Pagliuca Harvard Life Lab incubator, DCT has recently moved to the Biolabs Watertown incubator and has recently closed an investment from Atossa Therapeutics, a clinical-stage, publicly-traded company (ATOS). DCT is supported by an impressive team of scientific, clinical and business advisors, including Drs. Nikhil Munshi and Ken Anderson as well as Dr. Fred Mermelstein (CEO), a successful scientist and biotech entrepreneur.